Biopharmaceutical News and Research

RSS

New book offers fresh solutions for reducing poverty in developing world

Despite the vast wealth generated in the last half century, in today's world inequality is worsening and poverty is becoming increasingly chronic. Hundreds of millions of people continue to live on less than $2 per day and lack basic human necessities such as nutritious food, shelter, clean water, primary health care, and education.

13 Feb 2014

PAREXEL launches marketing initiative to simplify journey from science to new treatments

As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.

From Parexel 12 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients.

11 Feb 2014

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc.

11 Feb 2014

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).

10 Feb 2014

pSivida announces financial results for second quarter 2014

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.

10 Feb 2014

Eleven Biotherapeutics announces pricing of initial public offering of common stock

Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.

6 Feb 2014

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to standard antiepileptic drugs.

5 Feb 2014

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces it has entered into a multi-step collaboration with XOMA Corporation, a leader in the discovery and development of therapeutic antibodies.

4 Feb 2014

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

AbbVie today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

31 Jan 2014

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

Biogen Idec and UCB announced today that they have signed exclusive agreements granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both develop and commercialize products in China.

30 Jan 2014

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces new pre-clinical data demonstrating the inhibitory effects of GFT505 on the proliferation of cancer cells of different origins.

30 Jan 2014

Intelsius introduces revisions to PharmaTherm line of solutions

Intelsius, a DGP company, a designer, manufacturer and distributor of temperature-controlled packaging solutions, introduced revisions to its PharmaTherm™ line of solutions to pharmaceutical industry professionals today at the 13th Annual Cool Chain Europe Summit in Luxembourg.

28 Jan 2014

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013.

27 Jan 2014

ResearchDx expands operations to focus on Middle East clinical laboratory and diagnostics markets

ResearchDx, LLC of Irvine, California, USA today announced an expansion of its operations to focus on the important Middle East clinical laboratory and diagnostics markets.

27 Jan 2014

Hols conveys product’s safety and cost effectiveness to managed care groups

Health Outcomes Liaisons (HOLs) play a critical role in conveying a therapy's safety and cost effectiveness to managed care groups. With billions in sales riding on effectively communicating with these organizations regarding products' cost effectiveness and safety, the biopharmaceutical industry has turned to HOLs to fill this critical communication role.

27 Jan 2014

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a Phase 2 clinical trial to determine preliminary efficacy and safety of aldoxorubicin for HIV-infected patients with Kaposi's sarcoma.

23 Jan 2014

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S. Food & Drug Administration confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia.

23 Jan 2014

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas.

22 Jan 2014

Biopharmaceutical News and Research

New book offers fresh solutions for reducing poverty in developing world

PAREXEL launches marketing initiative to simplify journey from science to new treatments

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Ario Pharma begins XEN-0501 Phase IIa study for treatment persistent cough in COPD patients

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

pSivida announces financial results for second quarter 2014

Eleven Biotherapeutics announces pricing of initial public offering of common stock

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

Domain Therapeutics, XOMA to jointly evaluate DTect-All to identify allosteric modulator antibodies

AbbVie's global sales reduce 1.8% to $5.111B in fourth quarter 2013

Biogen Idec, UCB sign agreements to commercialize treatment of MS and hemophilia in Asia

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

Intelsius introduces revisions to PharmaTherm line of solutions

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

ResearchDx expands operations to focus on Middle East clinical laboratory and diagnostics markets

Hols conveys product’s safety and cost effectiveness to managed care groups

CytRx initiates aldoxorubicin Phase 2 trial in HIV-infected patients with Kaposi's sarcoma

BioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell mobilization treatment

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News